Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) is anticipated to release its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect the company to post earnings of ($1.10) per share and revenue of $182.49 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 5:00 PM ET.
Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.22) by $0.32. The business had revenue of $214.00 million for the quarter, compared to analysts’ expectations of $183.08 million. Ultragenyx Pharmaceutical’s revenue was up 28.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.17) EPS. On average, analysts expect Ultragenyx Pharmaceutical to post ($3.91) EPS for the current fiscal year and ($0.27) EPS for the next fiscal year.
Ultragenyx Pharmaceutical Stock Up 2.7%
Shares of Ultragenyx Pharmaceutical stock opened at $16.08 on Tuesday. The stock’s fifty day moving average is $17.74 and its two-hundred day moving average is $23.03. Ultragenyx Pharmaceutical has a 52 week low of $12.73 and a 52 week high of $39.89. The company has a market capitalization of $1.59 billion, a PE ratio of -2.75 and a beta of 0.35.
Wall Street Analyst Weigh In
A number of brokerages have recently issued reports on RARE. Robert W. Baird lowered shares of Ultragenyx Pharmaceutical from an “outperform” rating to a “neutral” rating and lowered their target price for the company from $40.00 to $16.00 in a research note on Thursday, September 3rd. Jefferies Financial Group reduced their price target on shares of Ultragenyx Pharmaceutical from $77.00 to $28.00 and set a “buy” rating on the stock in a research note on Thursday, September 3rd. Barclays raised their price target on shares of Ultragenyx Pharmaceutical from $32.00 to $35.00 and gave the stock an “overweight” rating in a research note on Monday, September 21st. Canaccord Genuity Group lifted their price objective on shares of Ultragenyx Pharmaceutical from $37.00 to $39.00 and gave the company a “buy” rating in a report on Friday, September 18th. Finally, Wells Fargo & Company cut shares of Ultragenyx Pharmaceutical from an “overweight” rating to an “equal weight” rating and lowered their price objective for the company from $50.00 to $18.00 in a research report on Thursday, September 3rd. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Ultragenyx Pharmaceutical presently has a consensus rating of “Hold” and an average price target of $33.65.
Get Our Latest Stock Report on Ultragenyx Pharmaceutical
Insider Buying and Selling
In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 7,066 shares of Ultragenyx Pharmaceutical stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $15.27, for a total transaction of $107,897.82. Following the completion of the sale, the chief financial officer directly owned 89,229 shares of the company’s stock, valued at $1,362,526.83. The trade was a 7.34% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 8,510 shares of company stock worth $127,561. Company insiders own 5.20% of the company’s stock.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare diseases. The company concentrates on conditions with significant unmet medical needs, including genetic, metabolic and endocrine disorders, and uses biologics, small molecules and gene therapy approaches in its research and development programs.
Ultragenyx’s commercial portfolio includes Crysvita (burosumab), a treatment for X-linked hypophosphatemia and related disorders; Mepsevii (vestronidase alfa), an enzyme replacement therapy for mucopolysaccharidosis VII; and Dojolvi (triheptanoin), a therapy for long-chain fatty acid oxidation disorders.
Featured Articles
- Five stocks we like better than Ultragenyx Pharmaceutical
- Verizon’s Q3 Results Show Why SpaceX’s Spectrum Grab Isn’t a Major Threat
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
